Added Clinically reviewed
TIMER framework Goodman, 2026
Biologic and targeted synthetic DMARD therapy in rheumatoid arthritis with prior malignancy
What TIMER is
Five components, one line each: what the record must contain
How the documentation zone is determined
Evidence context & authorship
TIMER is an original framework by Olga Goodman, MD. Its zones describe the proposed depth of deliberation and documentation; they are not cancer-risk estimates or EULAR categories. The worksheet does not select or recommend a medicine.
Smolen et al. EULAR recommendations for rheumatoid arthritis: 2025 update — published in 2026.
Sebbag et al. 2024 EULAR points to consider on targeted therapies in inflammatory arthritis with a history of cancer — the cancer-specific companion guidance.
Supporting systematic literature review and meta-analysis.
These publications provide clinical context; they do not validate or endorse TIMER. Worksheet version 1.0 · 24 September 2026. Website presentation · 25 September 2026.